<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Int</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Int</journal-id><journal-title-group><journal-title>Kidney International</journal-title></journal-title-group><issn pub-type="ppub">0085-2538</issn><issn pub-type="epub">1523-1755</issn><publisher><publisher-name>International Society of Nephrology. Published by Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35421508</article-id><article-id pub-id-type="pmc">PMC9001009</article-id><article-id pub-id-type="pii">S0085-2538(22)00272-1</article-id><article-id pub-id-type="doi">10.1016/j.kint.2022.04.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Chavarot</surname><given-names>Nathalie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Melenotte</surname><given-names>Clea</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Amrouche</surname><given-names>Lucile</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Rouzaud</surname><given-names>Claire</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Sberro-Soussan</surname><given-names>Rebecca</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Pavie</surname><given-names>Juliette</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Martinez</surname><given-names>Frank</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Pouvaret</surname><given-names>Anne</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Leruez-Ville</surname><given-names>Marianne</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Cantin</surname><given-names>Delphine</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Fourgeaud</surname><given-names>Jacques</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Delage</surname><given-names>Claire</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Vimpere</surname><given-names>Damien</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Peraldi</surname><given-names>Marie No&#x000eb;lle</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Legendre</surname><given-names>Christophe</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Lanternier</surname><given-names>Fanny</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Zuber</surname><given-names>Julien</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Scemla</surname><given-names>Anne</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Anglicheau</surname><given-names>Dany</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label>Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff2"><label>2</label>Universit&#x000e9; de Paris, Paris, France</aff><aff id="aff3"><label>3</label>Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff4"><label>4</label>Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique H&#x000f4;pitaux de Paris (APHP), Paris Centre H&#x000f4;tel-Dieu, Paris, France</aff><aff id="aff5"><label>5</label>Virology Laboratory, Necker Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff6"><label>6</label>COVID-19 Screening Center, Emergency Department, H&#x000f4;tel Dieu Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="aff7"><label>7</label>Adult Intensive Care Unit, Department of Anaesthesiology, Necker-Enfants Malades Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Correspondence:</bold> Nathalie Chavarot, Service de N&#x000e9;phrologie et Transplantation R&#x000e9;nale Adulte, H&#x000f4;pital Necker-Enfants Malades, 149, Rue de S&#x000e8;vres, 75015 Paris, France.</corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>4</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2022</year></pub-date><volume>101</volume><issue>6</issue><fpage>1290</fpage><lpage>1293</lpage><permissions><copyright-statement>&#x000a9; 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>International Society of Nephrology</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p content-type="salutation">To the editor:</p><p id="p0010">Early data about coronavirus disease 2019 (COVID-19) related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) suggest that it may be less severe than prior variants of concern in the general population.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> However, our preliminary data (NC, personal communication, January 28, 2022) about Omicron infection in kidney transplant recipients (KTRs) suggest that the disease is associated with severe forms in this vulnerable population with low postvaccinal immune responses.</p><p id="p0015">Sotrovimab monoclonal antibody has been demonstrated to reduce disease progression in high-risk patients with mild-to-moderate COVID-19 before the Omicron era.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Recent studies assessed that, in contrast with other monoclonal antibodies, it remained active against the Omicron spike.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>
</p><p id="p0020">We aimed to compare the clinical outcomes of the first 25 KTRs treated with sotrovimab for mild-to-moderate Omicron COVID-19 with KTRs who did not receive sotrovimab.</p><p id="p0025">Sotrovimab was available in our institution (Necker Hospital, Paris, France) from January 25, 2022. KTRs with a high risk for progression of COVID-19 (because of older age [&#x02265;55 years] or because they had at least 1 of the following risk factors: diabetes, obesity [body mass index &#x0003e;30, estimated glomerular filtration rate&#x000a0;&#x0003c;30 ml/min], coronary artery disease, or chronic lung disease) who presented with mild-to-moderate Omicron COVID-19 after this date were treated with sotrovimab (a single 500-mg, 1-hour infusion). The control group consisted of the first 100 consecutive KTRs who experienced Omicron infection before January 25. We excluded patients who received pre-exposure prevention with tixag&#x000e9;vimab/cilgavimab.</p><p id="p0030">A total of 25 patients (21 men [84%], median age of 54 years, interquartile range: 46&#x02013;62 years) who developed an Omicron infection between January 14 and February 13, 2022, received sotrovimab (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>
). Sixteen of 23 (69.6%) patients with available data had a COVID-19 serostatus predictive of a poor protection against Omicron (seronegative or weakly seropositive [&#x0003c;264 binding antibody units/ml] and/or treated with casirivimab/imdevimab). Antibody titers of seropositive patients are available in <xref rid="appsec1" ref-type="sec">Supplementary Table&#x000a0;S1</xref>). No infusion-related reaction was observed. Median time between symptom onset and sotrovimab infusion was 5 (interquartile range: 3&#x02013;9) days. (Eight patients [32%] were treated after day 5 [up to day 13] of symptom onset.) Although sotrovimab-treated patients presented more risk factors associated with severe COVID-19 (significantly more men and more underlying comorbidities; <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>), Omicron infection was less severe (less mortality and less severe disease [mortality and/or intensive care unit admission]) compared with controls (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>
). In the sotrovimab group, 4 (16.0%) patients were hospitalized, of whom, 1 patient required intensive care unit admission and no patients died. The patient admitted in intensive care unit received sotrovimab at day 11 after symptom onset. In contrast, 35 patients (35%) were hospitalized for Omicron disease in the control group. Among them, 17% required intensive care unit admission (9% needed mechanical ventilation) and 11% died.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Baseline and COVID-19 characteristics of KTRs infected with Omicron variant who received or not sotrovimab</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Sotrovimab-treated KTRs (N&#x000a0;= 25)</th><th>Nonsotrovimab-treated KTRs (N&#x000a0;= 100)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>Age, median (IQR)</td><td align="char">54 (46&#x02013;62)</td><td align="char">53 (37.8&#x02013;52)</td><td align="char">0.599</td></tr><tr><td>Sex (males), n (%)</td><td align="char">21 (84.0)</td><td align="char">54 (54.0)</td><td align="char"><bold>0.006</bold></td></tr><tr><td>BMI, kg/m<sup>2</sup>, median (IQR)</td><td align="char">24 (22&#x02013;25.6)</td><td align="char">25.5 (22.6&#x02013;30)</td><td align="char">0.162</td></tr><tr><td>BMI &#x0003e;30 kg/m<sup>2</sup>, n (%)</td><td align="char">2 (8.0)</td><td align="char">23 (24.5)</td><td align="char">0.101</td></tr><tr><td>Hypertension, n (%)</td><td align="char">20 (80.0)</td><td align="char">81 (82.7)</td><td align="char">0.773</td></tr><tr><td>Coronary artery disease, n (%)</td><td align="char">6 (24.0)</td><td align="char">13 (13.3)</td><td align="char">0.217</td></tr><tr><td>Diabetes mellitus, n (%)</td><td align="char">8 (32.0)</td><td align="char">34 (34.7)</td><td align="char">1.000</td></tr><tr><td>Chronic lung disease, n (%)</td><td align="char">5 (20.0)</td><td align="char">4 (4.1)</td><td align="char"><bold>0.017</bold></td></tr><tr><td>eGFR&#x000a0;&#x0003c;30 ml/min per 1.73 m<sup>2</sup>,<xref rid="tbl1fn1" ref-type="table-fn">a</xref> n (%)</td><td align="char">8 (32.0)</td><td align="char">7 (7.1)</td><td align="char"><bold>0.003</bold></td></tr><tr><td>KT &#x0003e;1, n (%)</td><td align="char">5 (20.0)</td><td align="char">21 (21)</td><td align="char">1.000</td></tr><tr><td><bold>Induction immunosuppressive therapy, n (%)</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Antithymocyte globulin</td><td align="char">7 (31.8)</td><td align="char">46 (46)</td><td align="char">0.246</td></tr><tr><td>&#x000a0;Basiliximab</td><td align="char">14 (63.6)</td><td align="char">44 (44)</td><td align="char">0.105</td></tr><tr><td>&#x000a0;Rituximab at induction</td><td align="char">4 (16)</td><td align="char">8 (8)</td><td align="char">0.256</td></tr><tr><td><bold>Maintenance immunosuppressive therapy</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Calcineurin inhibitors, n (%)</td><td align="char">20 (80.0)</td><td align="char">75 (75.0)</td><td align="char">0.794</td></tr><tr><td>&#x000a0;Azathioprine, n (%)</td><td align="char">2 (8.0)</td><td align="char">6 (6.0)</td><td align="char">0.660</td></tr><tr><td>&#x000a0;Mycophenolic acid, n (%)</td><td align="char">18 (72.0)</td><td align="char">84 (84.0)</td><td align="char">0.246</td></tr><tr><td>&#x000a0;Dose, mg/d, median (IQR)</td><td align="char">1000 (1000&#x02013;1500)</td><td align="char">1000 (1000&#x02013;1500)</td><td align="char">0.407</td></tr><tr><td>&#x000a0;mTOR-i (everolimus), n (%)</td><td align="char">1 (4.0)</td><td align="char">3 (3.0)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;Steroids, n (%)</td><td align="char">24 (96.0)</td><td align="char">96 (96.0)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;Dose, mg/d, median (IQR)</td><td align="char">8 (6&#x02013;10)</td><td align="char">7.5 (5&#x02013;10)</td><td align="char">0.179</td></tr><tr><td>&#x000a0;Belatacept, n (%)</td><td align="char">3 (12.0)</td><td align="char">21 (21.0)</td><td align="char">0.402</td></tr><tr><td><bold>Anti-SARS-2 mRNA vaccination (Pfizer&#x02013;BioNTech), n (%)</bold></td><td align="char">23 (92.0)</td><td align="char">88 (92.6)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;1 injection</td><td align="char">1 (4.0)</td><td align="char">1 (1.1)</td><td align="char">0.377</td></tr><tr><td>&#x000a0;2 injections</td><td align="char">1 (4.0)</td><td align="char">5 (5.3)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;3 injections</td><td align="char">16 (64)</td><td align="char">58 (61.1)</td><td align="char">0.822</td></tr><tr><td>&#x000a0;4 injections</td><td align="char">3 (12.0)</td><td align="char">24 (25.3)</td><td align="char">0.188</td></tr><tr><td><bold>Positive serology at Omicron infection, n (%)</bold></td><td align="char">7/23 (30.4)</td><td align="char">21/45 (46.7)</td><td align="char">0.298</td></tr><tr><td><bold>Anti-S titer, BAU/ml</bold></td><td align="char">192 (30&#x02013;744)</td><td align="char">260 (60&#x02013;1010)</td><td align="char">0.349</td></tr><tr><td>&#x000a0;Previous history of COVID-19, n (%)</td><td align="char">2 (8.0)</td><td align="char">13 (13)</td><td align="char">0.734</td></tr><tr><td><bold>Characteristics of Omicron infection</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Time between KT and Omicron infection, yr, median (IQR)</td><td align="char">7 (5&#x02013;14)</td><td align="char">6 (2.8&#x02013;11)</td><td align="char">0.140</td></tr><tr><td>&#x000a0;Clinical symptoms at presentation, n (%)</td><td align="center">N&#x000a0;= 23</td><td align="center">N&#x000a0;= 86</td><td/></tr><tr><td>&#x000a0;Cough</td><td align="char">16 (69.6)</td><td align="char">46 (51.1)</td><td align="char">0.236</td></tr><tr><td>&#x000a0;Asthenia</td><td align="char">10 (43.5)</td><td align="char">45 (50.0)</td><td align="char">0.489</td></tr><tr><td>&#x000a0;Fever</td><td align="char">14 (60.9)</td><td align="char">37 (41.1)</td><td align="char">0.160</td></tr><tr><td>&#x000a0;Rhinitis</td><td align="char">6 (26.1)</td><td align="char">36 (40.0)</td><td align="char">0.229</td></tr><tr><td>&#x000a0;Myalgia</td><td align="char">5 (21.7)</td><td align="char">31 (34.4)</td><td align="char">0.223</td></tr><tr><td>&#x000a0;Sore throat</td><td align="char">8 (34.8)</td><td align="char">30 (33.3)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;Diarrhea</td><td align="char">5 (21.7)</td><td align="char">23 (25.6)</td><td align="char">0.791</td></tr><tr><td>&#x000a0;Headache</td><td align="char">9 (39.1)</td><td align="char">22 (24.4)</td><td align="char">0.206</td></tr><tr><td>&#x000a0;Dyspnea</td><td align="char">0 (0)</td><td align="char">15 (16.7)</td><td align="char"><bold>0.037</bold></td></tr><tr><td>&#x000a0;Asymptomatic</td><td align="char">2 (8.7)</td><td align="char">7 (7.8)</td><td align="char">1.000</td></tr><tr><td>&#x000a0;Time between symptom onset and sotrovimab injection, d, median (IQR)</td><td align="char">5 (3&#x02013;9)</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x000a0;Follow-up after infection, d, median (IQR)</td><td align="char">30 (27&#x02013;34)</td><td align="char">20 (11&#x02013;27)</td><td align="char"><bold>0.011</bold></td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>BAU, binding antibody units; BMI, body mass index; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; IQR, interquartile range; KT, kidney transplantation; KTRs, kidney transplant recipients; mTOR, mammalian target of rapamycin; S, spike.</p></fn><fn id="tspara0020a"><p>Bold values of <italic>P</italic> &#x0003c; 0.05 were considered statistically significant.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn1"><label>a</label><p id="tspara0020">Determined with the Modification of Diet in Renal Disease equation.</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p><bold>Kaplan-Meier curves representing (a) mortality and (b) severe Omicron coronavirus disease 2019 (COVID-19) in kidney transplant recipients infected with Omicron variant and treated or not with sotrovimab</bold>.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0035">Omicron infection appears to be severe in KTRs. Our study reports the first cohort of KTRs treated with sotrovimab for Omicron infection. Although these patients presented high risk for progression to severe disease, the severity of COVID-19 was lower than the historical control group, concordant with findings in the general population. Interestingly, the rate of patients with SARS-CoV-2&#x02013;positive immune response was similar (and low) in both groups.</p><p id="p0040">Despite its retrospective character and the relatively short follow-up, our findings show that the sotrovimab-neutralizing anti-SARS-CoV-2 antibody can prevent severe COVID-19 in KTRs infected with the Omicron variant and can be safely proposed in outpatient KTRs.</p><sec id="sec1"><title>Data Statement</title><p id="p0045">The data that support the findings of this study are available from the corresponding author at <ext-link ext-link-type="uri" xlink:href="mailto:Nathalie.chavarot@aphp.fr" id="intref0010">Nathalie.chavarot@aphp.fr</ext-link>.</p></sec><sec id="sec2"><title>Disclosure</title><p id="p0050">All the authors declared no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Maslo</surname><given-names>C.</given-names></name><name><surname>Friedland</surname><given-names>R.</given-names></name><name><surname>Toubkin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves</article-title><source>JAMA</source><volume>327</volume><year>2022</year><fpage>583</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">34967859</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Ulloa</surname><given-names>A.C.</given-names></name><name><surname>Buchan</surname><given-names>S.A.</given-names></name><name><surname>Daneman</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>K.A.</given-names></name></person-group><article-title>Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada</article-title><source>JAMA</source><volume>327</volume><year>2022</year><fpage>1286</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">35175280</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Iuliano</surname><given-names>A.D.</given-names></name><name><surname>Brunkard</surname><given-names>J.M.</given-names></name><name><surname>Boehmer</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods&#x02014;United States, December 2020-January 2022</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>71</volume><year>2022</year><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">35085225</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Gonzalez-Rojas</surname><given-names>Y.</given-names></name><name><surname>Juarez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab</article-title><source>N&#x000a0;Engl J Med</source><volume>385</volume><year>2021</year><fpage>1941</fpage><lpage>1950</lpage><pub-id pub-id-type="pmid">34706189</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Schulz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic</article-title><source>Cell</source><volume>185</volume><year>2022</year><fpage>447</fpage><lpage>456.e11</lpage><pub-id pub-id-type="pmid">35026151</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="p0055">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary File (Word)</title></caption><media xlink:href="mmc1.docx"/></supplementary-material>
</p></sec><fn-group><fn id="appsec2" fn-type="supplementary-material"><p id="p0060">
<ext-link ext-link-type="doi" xlink:href="10.1016/j.kint.2022.04.003" id="intref0015">Supplementary File (Word)</ext-link>
</p><p id="p0065"><bold>Table&#x000a0;S1.</bold> Antispike titers in postvaccinal seropositive kidney transplant recipients treated or not with sotrovimab.</p></fn></fn-group></back></article>
